News in brief: Call for consistent OS reporting; Oncology researcher wins $3m Fellowship; Smoking associated with lower thyroid cancer risk

Call for consistent OS reporting on drugs Overall survival (OS) results should be clearly and consistently listed on cancer drug labels, health researchers argue. A review of FDA-approved cancer drugs found “substantial variation” in OS reporting, which could hinder prescribers’ identification of clinically significant or undetermined survival benefits. OS “is arguably the most definitive patient-relevant ...

Already a member?

Login to keep reading.

© 2022 the limbic